المؤلفون: Lim, Andrew, Grigoriadis, George, Walker, Trish, Nicol, Andrew, LeBlanc, Richard, Reece, Donna, Elemary, Mohamed, Boudreault Pedneault, Jean Samuel, Karlin, Lionel, Facon, Thierry, Attal, Michel, Weisel, Katja, Engelhardt, Monika, Mackensen, Andreas, Quinn, John, Avivi, Irit, Cohen, Amos, Magen-Nativ, Hila, Benyamini, Noam, Cavo, Michele, Larocca, Alessandra, Takezako, Naoki, Suzuki, Kenshi, Kosugi, Hiroshi, Matsumoto, Morio, Iida, Shinsuke, Ishikawa, Takayuki, Kondo, Yukio, Sunami, Kazutaka, Ando, Kiyoshi, Teshima, Takanori, Chou, Takaaki, Iwasaki, Hiromi, Miki, Hirokazu, Matsumura, Itaru, Onishi, Yasushi, Izutsu, Koji, Kizaki, Masahiro, George, Anupkumar, Blacklock, Hillary, Simpson, David, Schjesvold, Fredrik, Waage, Anders, Samoilova, Olga, Nikitin, Evgeniy, Chagorova, Tatiana, McDonald, Andrew, Patel, Moosa, Oriol Rocafiguera, Albert, San Miguel Izquierdo, Jesus, Mateos, Maria, Streetly, Matthew, Forsyth, Peter, Jackson, Graham, Jenkins, Stephen, Rifkin, Robert, Yimer, Habte, McCroskey, Robert, Martincic, Danko, Tarantolo, Stefano, Larson, Sarah, Faroun, Yacoub, Vaughn, Jennifer, Baz, Rachid, Saylors, Gene, Neppalli, Amarendra, Raptis, Anastasios, Fung, Henry, Janosky, Maxwell, Stevens, Don, Coleman, Morton, Costa, Dennis, Cross, Scott, Fanning, Suzanne, Berges, Daniel Farray, Harris, Thomas, Zackon, Ira, Atanackovic, Djordje, Lee, Kelvin, Oliff, Ira, Lee, Wes, Bensinger, William, Lutzky, Jose, Baron, Ari, Hayek, Fadi, Kirschner, Eli, Bharany, Neeraj, Overton, Lindsay, Mannem, Siva, Harroff, Allyson, Jain, Sharad, Roque, Tammy, McIntyre, Kristi, Yasencha, Christopher K, Houck, William, Usmani, Saad Zafar ^*, Oriol, Albert, Rifkin, Robert M, Yimer, Habte Aragaw, McCroskey, Robert Donald, Lim, Andrew Boon Ming, Jagannath, Sundar, Lonial, Sagar, Ghori, Razi Uddin, Farooqui, Mohammed Z H, Marinello, Patricia, San-Miguel, Jesus

المصدر: In The Lancet Haematology September 2019 6(9):e448-e458

المؤلفون: Usmani, Saad Zafar, Schjesvold, Fredrik Hellem, Oriol, Albert, Karlin, Lionel, Cavo, Michele, Rifkin, Robert M., Yimer, Habte Aragaw, LeBlanc, Richard, Takezako, Naoki, McCroskey, Robert Donald, Lim, Andrew Boon Ming, Suzuki, Kenshi, Kosugi, Hiroshi, Grigoriadis, George, Avivi, Irit, Facon, Thierry, Jagannath, Sundar, Lonial, Sagar, Ghori, Razi Uddin, Farooqui, Mohammed Z.H., Marinello, Patricia, San-Miguel, Jesús

المصدر: Usmani, Saad Zafar Schjesvold, Fredrik Hellem Oriol, Albert Karlin, Lionel Cavo, Michele Rifkin, Robert M. Yimer, Habte Aragaw LeBlanc, Richard Takezako, Naoki McCroskey, Robert Donald Lim, Andrew Boon Ming Suzuki, Kenshi Kosugi, Hiroshi Grigoriadis, George Avivi, Irit Facon, Thierry Jagannath, Sundar Lonial, Sagar Ghori, Razi Uddin Farooqui, Mohammed Z.H. Marinello, Patricia San-Miguel, Jesús . Pembrolizumab plus lenalidomide and dexamethasone for patients with treatment-naive multiple myeloma (KEYNOTE-185): a randomised, open-label, phase 3 trial. The Lancet Haematology. 2019, 6(9), e448-e458
The Lancet Haematology
e448
e458

الإتاحة: http://hdl.handle.net/10852/77065
https://www.duo.uio.no/bitstream/handle/10852/77065/5/Usmani%2BKN-185%2BManuscript_%2BRevised-D3-26March19%2B.pdf

المؤلفون: Usmani SZ; Levine Cancer Institute/Atrium Health, Charlotte, NC, USA. Electronic address: saad.usmani@carolinashealthcare.org., Schjesvold F; Oslo Myeloma Center, Oslo University Hospital and KG Jebsen Center for B-Cell Malignancies, University of Oslo, Oslo, Norway., Oriol A; Institut Català d'Oncologia and Institut Josep Carreras, Hospital Germans Trias i Pujol, Badalona, Spain., Karlin L; Centre Hospitalier Lyon-Sud, Pierre-Bénite, France., Cavo M; Seràgnoli Institute of Hematology, Bologna University School of Medicine, Bologna, Italy., Rifkin RM; Rocky Mountain Cancer Centers, Denver, CO, USA., Yimer HA; Texas Oncology, Tyler, TX, USA., LeBlanc R; Centre Intégré Universitaire de Santé et de Services Sociaux de l'Est de L'Ile de Montréal, University of Montreal, Montreal, QC, Canada., Takezako N; Disaster Medical Center, Tokyo, Japan., McCroskey RD; Northwest Medical Specialties, PLLC, Puyallup, WA, USA., Lim ABM; Austin Health, Austin Hospital, Heidelberg, VIC, Australia., Suzuki K; Japanese Red Cross Medical Center, Tokyo, Japan., Kosugi H; Ogaki Municipal Hospital, Ogaki, Japan., Grigoriadis G; Monash Health, Melbourne, VIC, Australia., Avivi I; Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel., Facon T; Hôpital Claude Huriez, Centre Hospitalier Régional Universitaire de Lille, Lille, France., Jagannath S; Mount Sinai Hospital, New York, NY, USA., Lonial S; Winship Cancer Institute, Emory University, Atlanta, GA, USA., Ghori RU; Merck & Co, Inc, Kenilworth, NJ, USA., Farooqui MZH; Merck & Co, Inc, Kenilworth, NJ, USA., Marinello P; Merck & Co, Inc, Kenilworth, NJ, USA., San-Miguel J; Clínica Universidad de Navarra, Centro de Investigación Médica Aplicada, Centro de Investigación Biomédica en Red de Cáncer, Instituto de Investigación Sanitaria de Navarra, Pamplona, Spain.

مؤلفون مشاركون: KEYNOTE-185 Investigators

المصدر: The Lancet. Haematology [Lancet Haematol] 2019 Sep; Vol. 6 (9), pp. e448-e458. Date of Electronic Publication: 2019 Jul 18.

نوع المنشور: Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial

بيانات الدورية: Publisher: Elsevier Ltd Country of Publication: England NLM ID: 101643584 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2352-3026 (Electronic) Linking ISSN: 23523026 NLM ISO Abbreviation: Lancet Haematol Subsets: MEDLINE

مواضيع طبية MeSH: Antibodies, Monoclonal, Humanized/*administration & dosage , Antineoplastic Combined Chemotherapy Protocols/*therapeutic use , Dexamethasone/*administration & dosage , Lenalidomide/*administration & dosage , Multiple Myeloma/*drug therapy, Aged ; Aged, 80 and over ; Antibodies, Monoclonal, Humanized/adverse effects ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Dexamethasone/adverse effects ; Female ; Humans ; Lenalidomide/adverse effects ; Male ; Multiple Myeloma/mortality ; Multiple Myeloma/pathology ; Pneumonia/etiology ; Progression-Free Survival ; Proportional Hazards Models ; Survival Rate ; Treatment Outcome